135 related articles for article (PubMed ID: 27660687)
1. Polar Recognition Group Study of Keap1-Nrf2 Protein-Protein Interaction Inhibitors.
Lu MC; Tan SJ; Ji JA; Chen ZY; Yuan ZW; You QD; Jiang ZY
ACS Med Chem Lett; 2016 Sep; 7(9):835-40. PubMed ID: 27660687
[TBL] [Abstract][Full Text] [Related]
2. Structure-activity relationships of 1,4-bis(arylsulfonamido)-benzene or naphthalene-N,N'-diacetic acids with varying C2-substituents as inhibitors of Keap1-Nrf2 protein-protein interaction.
Lee S; Abed DA; Nguyen MU; Verzi MP; Hu L
Eur J Med Chem; 2022 Jul; 237():114380. PubMed ID: 35462166
[TBL] [Abstract][Full Text] [Related]
3. Discovery of benzo[g]indoles as a novel class of non-covalent Keap1-Nrf2 protein-protein interaction inhibitor.
Yasuda D; Yuasa A; Obata R; Nakajima M; Takahashi K; Ohe T; Ichimura Y; Komatsu M; Yamamoto M; Imamura R; Kojima H; Okabe T; Nagano T; Mashino T
Bioorg Med Chem Lett; 2017 Nov; 27(22):5006-5009. PubMed ID: 29037947
[TBL] [Abstract][Full Text] [Related]
4. Discovery of potent Keap1-Nrf2 protein-protein interaction inhibitor based on molecular binding determinants analysis.
Jiang ZY; Lu MC; Xu LL; Yang TT; Xi MY; Xu XL; Guo XK; Zhang XJ; You QD; Sun HP
J Med Chem; 2014 Mar; 57(6):2736-45. PubMed ID: 24512214
[TBL] [Abstract][Full Text] [Related]
5. Structure-Activity and Structure-Property Relationship and Exploratory in Vivo Evaluation of the Nanomolar Keap1-Nrf2 Protein-Protein Interaction Inhibitor.
Jiang ZY; Xu LL; Lu MC; Chen ZY; Yuan ZW; Xu XL; Guo XK; Zhang XJ; Sun HP; You QD
J Med Chem; 2015 Aug; 58(16):6410-21. PubMed ID: 26258437
[TBL] [Abstract][Full Text] [Related]
6. Discovery of direct inhibitors of Keap1-Nrf2 protein-protein interaction as potential therapeutic and preventive agents.
Abed DA; Goldstein M; Albanyan H; Jin H; Hu L
Acta Pharm Sin B; 2015 Jul; 5(4):285-99. PubMed ID: 26579458
[TBL] [Abstract][Full Text] [Related]
7. Discovery of a head-to-tail cyclic peptide as the Keap1-Nrf2 protein-protein interaction inhibitor with high cell potency.
Lu MC; Jiao Q; Liu T; Tan SJ; Zhou HS; You QD; Jiang ZY
Eur J Med Chem; 2018 Jan; 143():1578-1589. PubMed ID: 29117896
[TBL] [Abstract][Full Text] [Related]
8. Discovery of a Potent Kelch-Like ECH-Associated Protein 1-Nuclear Factor Erythroid 2-Related Factor 2 (Keap1-Nrf2) Protein-Protein Interaction Inhibitor with Natural Proline Structure as a Cytoprotective Agent against Acetaminophen-Induced Hepatotoxicity.
Lu MC; Zhang X; Wu F; Tan SJ; Zhao J; You QD; Jiang ZY
J Med Chem; 2019 Jul; 62(14):6796-6813. PubMed ID: 31283229
[TBL] [Abstract][Full Text] [Related]
9. Nrf2 activation through the inhibition of Keap1-Nrf2 protein-protein interaction.
Lee S; Hu L
Med Chem Res; 2020 May; 29(5):846-867. PubMed ID: 32390710
[TBL] [Abstract][Full Text] [Related]
10. CPUY192018, a potent inhibitor of the Keap1-Nrf2 protein-protein interaction, alleviates renal inflammation in mice by restricting oxidative stress and NF-κB activation.
Lu MC; Zhao J; Liu YT; Liu T; Tao MM; You QD; Jiang ZY
Redox Biol; 2019 Sep; 26():101266. PubMed ID: 31279986
[TBL] [Abstract][Full Text] [Related]
11. Pterostilbene-mediated Nrf2 activation: Mechanistic insights on Keap1:Nrf2 interface.
Bhakkiyalakshmi E; Dineshkumar K; Karthik S; Sireesh D; Hopper W; Paulmurugan R; Ramkumar KM
Bioorg Med Chem; 2016 Aug; 24(16):3378-86. PubMed ID: 27312421
[TBL] [Abstract][Full Text] [Related]
12. Molecular recognition between potential natural inhibitors of the Keap1-Nrf2 complex.
Bello M; Morales-González JA
Int J Biol Macromol; 2017 Dec; 105(Pt 1):981-992. PubMed ID: 28746889
[TBL] [Abstract][Full Text] [Related]
13. Discovery and Development of Kelch-like ECH-Associated Protein 1. Nuclear Factor Erythroid 2-Related Factor 2 (KEAP1:NRF2) Protein-Protein Interaction Inhibitors: Achievements, Challenges, and Future Directions.
Jiang ZY; Lu MC; You QD
J Med Chem; 2016 Dec; 59(24):10837-10858. PubMed ID: 27690435
[TBL] [Abstract][Full Text] [Related]
14. A Comparative Assessment Study of Known Small-Molecule Keap1-Nrf2 Protein-Protein Interaction Inhibitors: Chemical Synthesis, Binding Properties, and Cellular Activity.
Tran KT; Pallesen JS; Solbak SMØ; Narayanan D; Baig A; Zang J; Aguayo-Orozco A; Carmona RMC; Garcia AD; Bach A
J Med Chem; 2019 Sep; 62(17):8028-8052. PubMed ID: 31411465
[TBL] [Abstract][Full Text] [Related]
15. Non-covalent Small-Molecule Kelch-like ECH-Associated Protein 1-Nuclear Factor Erythroid 2-Related Factor 2 (Keap1-Nrf2) Inhibitors and Their Potential for Targeting Central Nervous System Diseases.
Pallesen JS; Tran KT; Bach A
J Med Chem; 2018 Sep; 61(18):8088-8103. PubMed ID: 29750408
[TBL] [Abstract][Full Text] [Related]
16. Emerging Screening Approaches in the Development of Nrf2-Keap1 Protein-Protein Interaction Inhibitors.
Leung CH; Zhang JT; Yang GJ; Liu H; Han QB; Ma DL
Int J Mol Sci; 2019 Sep; 20(18):. PubMed ID: 31509940
[TBL] [Abstract][Full Text] [Related]
17. A systematic molecular dynamics approach to the study of peptide Keap1-Nrf2 protein-protein interaction inhibitors and its application to p62 peptides.
Lu MC; Yuan ZW; Jiang YL; Chen ZY; You QD; Jiang ZY
Mol Biosyst; 2016 Apr; 12(4):1378-87. PubMed ID: 26935067
[TBL] [Abstract][Full Text] [Related]
18. Identification of compounds that inhibit the binding of Keap1a/Keap1b Kelch DGR domain with Nrf2 ETGE/DLG motifs in zebrafish.
Raghunath A; Nagarajan R; Sundarraj K; Palanisamy K; Perumal E
Basic Clin Pharmacol Toxicol; 2019 Sep; 125(3):259-270. PubMed ID: 30861618
[TBL] [Abstract][Full Text] [Related]
19. Nuclear factor (erythroid-derived 2)-like 2 (NRF2) drug discovery: Biochemical toolbox to develop NRF2 activators by reversible binding of Kelch-like ECH-associated protein 1 (KEAP1).
Bresciani A; Missineo A; Gallo M; Cerretani M; Fezzardi P; Tomei L; Cicero DO; Altamura S; Santoprete A; Ingenito R; Bianchi E; Pacifici R; Dominguez C; Munoz-Sanjuan I; Harper S; Toledo-Sherman L; Park LC
Arch Biochem Biophys; 2017 Oct; 631():31-41. PubMed ID: 28801166
[TBL] [Abstract][Full Text] [Related]
20.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Next] [New Search]